Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Girish Bhatia
Observed names:
G. Bhatia,
GIRISH BHATIA
Observed institution:
Zydus Lifesciences Limited (India)
ORCID:
0009-0007-1029-3395
Observed ORCID:
0009-0007-1029-3395
OpenAlex ID:
A5000721151
A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC ‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
2015
·
Rajendrakumar H. Jani
, Rajiv Gupta
, et al.
·
International Journal of Rheumatic Diseases
·
62
PDF
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
2020
·
Manjunath Krishnappa
, Kishor Patil
, et al.
·
Cardiovascular Diabetology
·
53
PDF
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
2019
·
Hisashi Yamanaka
, Naoyuki Kamatani
, et al.
·
Rheumatology and Therapy
·
20
PDF
OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses
2014
·
J. Kay
, A. Chopra
, et al.
·
Annals of the Rheumatic Diseases
·
16
A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin
2023
·
Aditi Jain
, Abhay Vispute
, et al.
·
Diabetes Therapy
·
13
PDF
A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
2024
·
Awadhesh Kumar Singh
, Rakesh Sahay
, et al.
·
International Journal of Diabetes in Developing Countries
·
10
PDF
AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses
2015
·
J. Kay
, A. Chopra
, et al.
·
Annals of the Rheumatic Diseases
·
6
Comparison of the efficacy and safety of biosimilar adalimumab injection with innovator adalimumab in subjects with active ankylosing spondylitis
2023
·
Chandrashekara S
, Jyoti Ranjan Parida
, et al.
·
Research Square
·
1
PDF
Six Months Comparative Evaluation of Efficacy and Safety of Wockhardt's Biosimilar Insulin Glargine (Glaritus®) with Reference Insulin Glargine (Lantus®) in Type 2 Diabetes Mellitus in India: Results of Interim Analysis
2020
·
S. K. Sharma
, A. K. Ajmani
, et al.
·
Advances in Diabetes and Metabolism
·
1
PDF
Ab0416 a Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of Ylb113 and Etanercept Reference Product for the Treatment of Patients With Active Rheumatoid Arthritis
2019
·
Hisashi Yamanaka
, Naoyuki Kamatani
, et al.
·
Annals of the Rheumatic Diseases
·
1
Immunogenicity, Safety and Efficacy Comparison of Wockhardt’s Biosimilar Insulin Glargine—Glaritus® with Reference Product— Lantus®: Study Protocol & Early Data Trends
2018
·
S. K. Sharma
, A. K. Ajmani
, et al.
·
Open Journal of Endocrine and Metabolic Diseases
·
1
PDF
A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis
2025
·
Nitin Kapoor
, Thomas Paul
, et al.
·
Aging Medicine
PDF
1113-P: Six Months Comparative Evaluation of Efficacy and Safety of Wockhardt’s Biosimilar Insulin Glargine (Glaritus®) with Reference Insulin Glargine (Lantus®) in Type 2 Diabetes Mellitus in India
2019
·
SURENDRA SHARMA
, AJAY KUMAR AJMANI
, et al.
·
Diabetes
A phase 3, randomized, bouble-blind, active comparator study of the efficacy and safety of bBow015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses
2014
·
Arvind Chopra
, Jonathan Kay
, et al.
·
Indian Journal of Rheumatology
Show more works
View as search
Works count:
15
Citation count:
184
H-index:
6
I10-index:
6
Year
Topic
Type
